InvestoGain

Investogain Pty Limited
AFS Licence No. 334036

All correspondence to:
admin@delisted.com.au
or by mail to:
PO Box 400
Crows Nest NSW 1585

26 April 2025

Name:	SIENNA CANCER DIAGNOSTICS LIMITED (SDX)
ISIN:	AU000000SDX1
Date of Listing:	03 August 2017
Date of Delisting:	29 July 2020

Stock Exchange Status: (updated daily)

This entity was delisted from the Australian Securities Exchange on 29 July 2020.

Legal Status: (updated monthly)

To our knowledge this entity was the subject of a takeover or merger such that your securities were acquired for consideration in the form of cash or scrip. We have not therefore verified the current legal status of this entity. If you have questions about your shareholding, as we say elsewhere, they may be taken up here: https://www.delisted.com.au/TraceLostSharesLostMoney/index/.

Capital Gains Tax (CGT) Status: (updated at least quarterly)

To our knowledge this entity was the subject of a takeover or merger such that your securities were acquired for consideration in the form of cash or scrip. You will need to seek independent tax advice in relation to Capital Gains Tax or other tax matters but any other enquiries relating to your shareholding in the company should be followed up via our online form here: https://www.delisted.com.au/TraceLostSharesLostMoney/index/.

Updates, corrections, disagreements please email to admin@delisted.com.au

Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.

Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.

Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.

SIENNA CANCER DIAGNOSTICS LIMITED(SDX)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

Shareholder links

Our website ranking of SDX:

(3 out of 5)

COMPANY WEBSITE:

SDX website

SDX email

SDX investorRelations

SDX directors

REGISTRY:

Tower 4, 727 Collins Street Docklands VIC 3008

Tel : +61 3 9615 9800 or 61 1300 554 474
Fax : +61 2 9287 0303
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000SDX1

Address: 23 Normanby Rd Notting Hill, Victoria 3168
Tel: 03 8288 2141 Fax: 03 8288 2059

Date first listed: 03/08/2017
Company Secretary:
Sector: Pharmaceuticals, Biotechnology & Life Sciences Industry Group:
Activities: Biotechnology and life science

News & Events

Expand this box to read and print

delisted from the close of trading on Wednesday, 29 July 2020, pursuant to Listing rule 17.11.	29/07/2020
we understand BARD1 Life Sciences was successful with an offer of 13 new ordinary shares in BARD1 for every 5 Sienna shares	29/07/2020
The scheme of arrangement between Sienna and its shareholders in relation to the acquisition of all shares in Sienna by BARD1 Life Sciences was implemented today. This follows approval by shareholders on 15 July 2020 and approval of the scheme by the Federal Court of Australia on 20 July 2020. Eligible former Sienna shareholders have been issued 13 new ordinary shares in BARD1 for every 5 Sienna shares they held as at the Scheme record date being 23 July 2020.	28/07/2020
The securities of Sienna Cancer Diagnostics Limited will be suspended from quotation at the close of trading today, Monday, 20 July 2020, in accordance with Listing Rule 17.2, following lodgement of the Federal Court of Australia orders with the Australian Securities and Investments Commission approving the scheme of arrangement by which BARD1 Life Sciences Limited will acquire all of the issued shares in SDX.	20/07/2020
The suspension of trading in the securities of Sienna Cancer Diagnostics Limited will be lifted immediately, following the release by SDX of an announcement regarding a capital raising.	29/11/2019
Sienna to raise up to approximately $4.2 million, before costs, via a share placement and rights issue at 3.5 cents per share. Issue price of 3.5 cents per share represents a 20% discount to the 30-day Volume Weighted Average Price (VWAP) of Sienna's shares traded on the ASX as at 25 November 2019, and a 13% premium to the last traded price of Sienna shares (being 3.1 cents on 25 November 2019). Funds will be used for further development of SIEN NETTM, co-development expenditures for the collaborative agreements with Minomic International Ltd and VivaZome Therapeutics Pty Ltd, and continued evaluation of potential technologies for acquisition or in-license.	29/11/2019
The securities of Sienna Cancer Diagnostics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of SDX, pending the release of an announcement regarding a capital raising.	28/11/2019
listed entity carried for record purposes only	03/08/2017

ASX Announcements (courtesy of ASX)

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

Company Updates

Post your comments here

Please read our Terms before posting comments.

Click here for free access to this company's:
ASX, Legal & CGT Status

Directors' on-market share transactions (last 5)

Purchases Sales

DATE	DIRECTOR	NUMBER	PRICE	AMOUNT
13/09/2017	John Chiplin	75,000	$0.140	$10,500.00

Click here for the last 20 transactions all companies

Directors & Executives (current)

NAME	TITLE	DATE OF APPT
Helen Fisher	Independent Director	28/03/2018
Philip Powell	Non Exec Director	28/07/2020
Geoffrey Cumming	Non Exec Director	27/01/2006

Date of first appointment, title may have changed.

Directors & Executives (former)

NAME	TITLE	DATE OF APPOINTMENT	DATE OF RESIGNATION

Date of first appointment, title may have changed.